Guerbet

Guerbet: 2021 revenue

10 фев 2022 08:54:31 Источник Nasdaq GlobeNewswire

Guerbet: 2021 Corporate Social Responsibility Gaïa-Index: Guerbet consolidates its position as leader in the “Healthcare” category

04 янв 2022 09:02:01 Источник Nasdaq GlobeNewswire

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

13 дек 2021 22:00:00 Источник Nasdaq GlobeNewswire

Guerbet: Revenue at September 30, 2021

21 окт 2021 08:46:04 Источник Nasdaq GlobeNewswire

Guerbet: Guerbet contributes to the NH TherAguix IPO on Euronext Growth, a specialist in innovative biotechnologies for precision radiotherapy

29 сен 2021 09:00:54 Источник Nasdaq GlobeNewswire

Guerbet: 2021 half-year results

22 сен 2021 08:54:05 Источник Nasdaq GlobeNewswire

Guerbet: Revenue at June 30, 2021

22 июл 2021 08:46:33 Источник Nasdaq GlobeNewswire

Marc Massiot appointed to Guerbet’s Board of Directors

31 май 2021 09:00:00 Источник Nasdaq GlobeNewswire

Guerbet: Q1 2021 revenue

22 апр 2021 08:45:00 Источник Nasdaq GlobeNewswire

Guerbet: Additional information related to 2021 financial outlook

28 мар 2021 23:25:59 Источник Nasdaq GlobeNewswire

Guerbet: 2020 annual results

24 мар 2021 09:45:00 Источник Nasdaq GlobeNewswire

Guerbet: Gadopiclenol - positive results for Phase III clinical trials

24 мар 2021 00:00:00 Источник Nasdaq GlobeNewswire

Guerbet: Revenue 2020

11 фев 2021 08:45:00 Источник Nasdaq GlobeNewswire